Volume Alert - CANF 3.64 Can-Fite Biopharma Ltd Sponsore

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - CANF 3.64 Can-Fite Biopharma Ltd Sponsore $CANF Hit a high today of 3.98 Closing the day 10:30 at 3.64 -0.18 -4.71% With a day low of 3.56 and a total volume of 1,141,053.

CANF Recent Posts: http://investorshangout.com/Can-Fite-Biopharm...ANF-88432/

CANF Can-Fite Biopharma Ltd Sponsore Recent Headline News

BUYINS.NET Issues Can-Fite BioPharma (CANF) SqueezeTrigger Report
M2 - Thu Nov 20, 6:55AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Can-Fite BioPharma (NYSE MKT: CANF) after releasing the latest short sale data through November 18, 2014. The total aggregate number of shares shorted since December 2013 is approximately 2.19 million shares. Approximately 23.65% of daily trading volume is short selling. The SqueezeTrigger price for all CANF shares shorted is $4.89. A short squeeze is expected to begin when shares of CANF close above the $4.89 SqueezeTrigger price.
CANF: 3.97 (+0.15)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 4:38PM CST

CANF: 3.97 (+0.15), HI: 33.95 (+0.97), IRT: 9.37 (-0.52), JMEI: 19.94 (-2.29), WSM: 75.94 (+6.52), CLD: 11.99 (+0.56), CZR: 15.08 (+0.71), SBGL: 7.69 (+0.15), CRM: 58.36 (-2.66), SMTC: 24.69 (+0.41)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 11:55AM CST

CLUB: 6.35 (+0.28), LEJU: 11.59 (-0.48), ANV: 1.69 (+0.20), SSI: 19.40 (+0.61), ROX: 1.80 (+0.12), CLF: 8.72 (+0.55), BIND: 7.73 (-0.67), NADL: 3.19 (+0.03), CSTM: 17.36 (-0.57), VRML: 1.46 (-0.04), WTT: 2.74 (+0.14), CANF: 3.97 (+0.15), DL: 17.74 (unch), BAMM: 1.98 (+0.33), RELV: 1.29 (+0.01), SNCR: 43.16 (+0.91), ATLC: 2.51 (-0.09), AGIO: 93.03 (-2.94), BBLU: 1.14 (+0.03), OPLK: 24.19 (+0.01)

Small Cap IR Initiates Coverage of Can-Fite Biopharma: Newly Discovered Late Clinical Stage BioPharma Vendor with Potentially Revolutionary Breakthroughs
PR Newswire - Wed Nov 19, 6:30AM CST
Analyst report by Small Cap IR - Can-Fite BioPharma Ltd. (NYSEMKT: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion markets in the treatment of inflammatory diseases, cancer, sexual dysfunction, and ophthalmic indications. The Company is conducting Phase I, II and III clinical trials for numerous indications in the U.S., Europe and Israel. Can-Fite currently maintains 14 patent families that include 74 international patents issued and pending and its science is well-founded with articles in 48 peer reviewed journals.
CANF: 3.97 (+0.15)

Can-Fite shows some life
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 12:05PM CST

CANF: 3.97 (+0.15)

Can-Fite Near-Term Milestones Timetable for 2014/2015
PR Newswire - Tue Nov 18, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced several upcoming and near-term milestones on its CF101 and CF102 indications for liver cancer, rheumatoid arthritis, psoriasis, glaucoma and the development of a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).
CANF: 3.97 (+0.15)

Can-Fite Announces Special General Meeting of Shareholders to Elect External Director
PR Newswire - Mon Nov 17, 4:48PM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it is convening a Special General Meeting of Shareholders on Wednesday, December 24, 2014 at 10:00 a.m. (Israel time) at Can-Fite's offices located at 10 Bareket Street, Petach Tikva, Israel. The record date for shareholders entitled to vote at the meeting is close of business on November 26, 2014.
CANF: 3.97 (+0.15)

Can-Fite CEO Dr. Pnina Fishman to Present Recently Released Positive Data from its Rheumatoid Arthritis Phase IIb Study at the 2014 American College of Rheumatology Annual Meeting
PR Newswire - Thu Nov 13, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that the Company's CEO, Dr. Pnina Fishman, will present at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP)'s 2014 Annual Meeting. The meeting will take place in Boston, Massachusetts, from November 14-19, 2014.
CANF: 3.97 (+0.15)

Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST

CANF: 3.97 (+0.15), JNJ: 108.06 (-0.70), IDRA: 2.57 (+0.02), DERM: 16.19 (+0.18), MRK: 59.25 (-0.39), PFE: 30.47 (+0.03), AZN: 74.22 (-1.16), AMGN: 164.47 (+1.83), GSK: 46.49 (+0.24), HSP: 58.60 (-0.21), NVS: 95.51 (-0.22), CELG: 107.27 (+0.29)

Can-Fite to Participate in BIO-Europe International Partnering Conference
PR Newswire - Thu Oct 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that the Company's CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman, will participate in approximately 40 scheduled one-on-one meetings with potential industry partners at BIO-Europe® in Frankfurt, Germany on November 3 to 5, 2014.
CANF: 3.97 (+0.15)

Ad Comm backs approval of secukinumab
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 6:32AM CDT

CANF: 3.97 (+0.15), JNJ: 108.06 (-0.70), IDRA: 2.57 (+0.02), DERM: 16.19 (+0.18), PFE: 30.47 (+0.03), AZN: 74.22 (-1.16), MRK: 59.25 (-0.39), AMGN: 164.47 (+1.83), HSP: 58.60 (-0.21), CELG: 107.27 (+0.29), NVS: 95.51 (-0.22)

Ad Comm meeting approaches for Novartis' psoriasis therapy candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 10:46AM CDT

CANF: 3.97 (+0.15), JNJ: 108.06 (-0.70), IDRA: 2.57 (+0.02), DERM: 16.19 (+0.18), PFE: 30.47 (+0.03), AZN: 74.22 (-1.16), MRK: 59.25 (-0.39), AMGN: 164.47 (+1.83), HSP: 58.60 (-0.21), CELG: 107.27 (+0.29), NVS: 95.51 (-0.22)

Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 3.97 (+0.15), AMPE: 3.42 (-0.07), CEMP: 13.46 (+0.24), CORT: 3.06 (+0.08)

Can-Fite CEO Dr. Pnina Fishman to Co-Chair and Present at the 19th World Congress on Advances in Oncology's Cancer Therapeutics Session
PR Newswire - Tue Oct 07, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the Company's CEO, Dr. Pnina Fishman, will co-chair the Cancer Therapeutics session of the 19th World Congress on Advances in Oncology. The conference will take place in Athens, Greece, from October 9-11, 2014.
CANF: 3.97 (+0.15)

U.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
PR Newswire - Tue Sep 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the United States Patent and Trademark Office has issued a patent to the Company which covers its drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery. The issued patent # 8,846,635 is titled, "Method for inducing hepatocyte proliferation and uses thereof." Can-Fite has recently been granted a patent for this technology in Japan and the European Union.
CANF: 3.97 (+0.15)

Can-Fite Files June 30, 2014 Interim Financial Statements
PR Newswire - Wed Sep 17, 2:02PM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its unaudited interim consolidated financial statements as of June 30, 2014 and an operating and financial review for such period with the U.S. Securities and Exchange Commission. The filing can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov.
CANF: 3.97 (+0.15)

Can Fite's Drug CF101 is Presented in Scientific Journal as One of Four Small Molecule Drugs for the Treatment of Psoriasis
PR Newswire - Wed Sep 17, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that an article titled, "New Drugs and Treatment Targets in Psoriasis," published in the peer-reviewed scientific journal Acta Derm Venereologica, cites the Company's CF101 as a potential treatment for psoriasis. The article was written by researchers at the Department of Dermato-allergology, Gentofte Hospital, University of Copenhagen, Denmark. To read the article in full, please visit: Acta Derm Venereologica.
CANF: 3.97 (+0.15)

Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
CANF: 3.97 (+0.15), ECYT: 6.26 (-0.04), ENZ: 4.31 (-0.19), PFE: 30.46 (+0.02), ABBV: 65.45 (-0.05), XOMA: 4.59 (+0.48), NVS: 95.51 (-0.22)

Can-Fite BioPharma receives Japanese patent for liver regeneration clinical stage drug candidate CF102
M2 - Mon Sep 08, 5:27AM CDT
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) (Tel Aviv:CFBI.TA) reported on Friday the receipt of the patent, titled 'Method for inducing hepatocyte proliferation and uses thereof', from the Japanese Patent Office.
CANF: 3.97 (+0.15)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 114

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 99

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 0

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 52

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 305

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 319

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 24

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 13

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 225

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

UP Oncolytics Boosts Funding to Propel Brain Cancer Research

Updated Category News Views 171

UP Oncolytics Secures Significant Grant for Research Advancement UP Oncolytics, a pioneering biotechnology company specializing in neuro-oncology, is making headlines with its latest achievement in funding. This innovative company, a spin-out from a prominent research institution, has secured a matching grant to further its mission in developing oncolytic virus therapy...

Continue Reading
US Dollar Weakness Fuels Gold's Safe Haven Appeal Amid Trade Tensions

Updated Category News Views 269

US Dollar Weakness Benefits Gold Amid Trade Concerns The US dollar has been retreating against several major currencies, largely influenced by recent dovish comments from Fed Governor Waller. The anticipation of further developments in trade negotiations is another factor keeping investors on edge as they navigate these financial currents. Fed’s Influence on the Dollar...

Continue Reading
Tesla's Strategic Partnerships with Local Suppliers in China

Updated Category News Views 468

Tesla's Strategic Partnerships with Local Suppliers in China Tesla, Inc. (NASDAQ: TSLA) is taking significant steps to enhance its operational efficiency and local presence in the world's largest automotive market, China. Recently reported developments indicate that the iconic electric vehicle manufacturer has successfully established partnerships with over 400 local...

Continue Reading
Collect a Unique Piece of History: Trump Bobblehead Release

Updated Category News Views 324

Royal Bobbles Launches Limited Edition Bobblehead of President-Elect Trump Add an Iconic Piece of Presidential Inauguration History with a One-of-a-Kind President-Elect Donald J. Trump Bobblehead A Historic Collectible Honoring Strength and Patriotism Royal Bobbles, recognized as the original bobblehead maker, has made an exciting announcement. They are launching the 2025...

Continue Reading
Extant Capital's New $200 Million Investment Marks Growth Path

Updated Category News Views 219

Extant Capital Receives Significant Investment Boost Extant Capital, an alternative asset management firm, has made an exciting announcement regarding a substantial new investment. The firm has successfully secured a $200 million cornerstone investment from New Holland Capital, marking a pivotal moment in its growth journey. This strategic partnership is set to enhance...

Continue Reading